



Integra LifeSciences to Present At Upcoming Merrill Lynch and First Albany Healthcare Conferences

PLAINSBORO, N.J., Feb. 1, 2007 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference at the Grand Hyatt Hotel in New York City on Tuesday, February 6, 2007 and at the First Albany Capital Second Annual Orthopedics Conference at Marina Village in San Diego on Tuesday, February 13, 2007.

The Merrill Lynch presentation will be delivered by Stuart Essig, President and Chief Executive Officer of Integra. A live webcast of this presentation can be accessed through a link provided on the home page of the Investor Relations section of Integra's website at <http://www.Integra-LS.com>. Additionally, a replay of the webcast will be available through Tuesday, February 20, 2007.

The First Albany presentation will be delivered by Gerard Carlozzi, Executive Vice President and Chief Operating Officer. This presentation will not be available via webcast.

Each of the presentations will provide an overview of Integra's operations, with a focus on currently marketed products, sales distribution channels, and product pipeline, recent financial history, and Integra's overall business strategy for growth.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President,
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com
John Bostjancic, Vice President, Corporate Development and
Investor Relations
(609) 936-2239
jbostjancic@integra-LS.com